• Explore /
  • Poster
  • / Real-world analysis of patient characteristics and outcomes among patients with metastatic colorectal cancer receiving trifluridine/tipiracil (FTD/TPI) plus bevacizumab versus FTD/TPI monotherapy.

Real-world analysis of patient characteristics and outcomes among patients with metastatic colorectal cancer receiving trifluridine/tipiracil (FTD/TPI) plus bevacizumab versus FTD/TPI monotherapy.

Abstract Poster

Authors

Joleen Hubbard

Joleen M. Hubbard

Allina Health, Minneapolis, MN

Joleen M. Hubbard , Lulu K. Lee , Jay L. Grisolano , Kacper Perkowski , Tehseen Salimi , Reza Kazerooni , Robert S. Epstein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 34)

DOI

10.1200/JCO.2024.42.3_suppl.34

Abstract #

34

Poster Bd #

C15

Abstract Disclosures

Similar Posters

First Author: Timothy Jay Price

First Author: Andrew Trunk

First Author: Catherine Pham

First Author: Marwan Fakih